Estrella Immunopharma annual operating cash flow
2021
2022
2022
2023
2024
2024
2025
Estrella Immunopharma Operating Cash Flow Growth & History (ESLA)
Estrella Immunopharma's operating cash flow was −$1.8M for fiscal 2025.
View full Estrella Immunopharma company overviewEstrella Immunopharma annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$1.8M | $1.3M | — |
| 2024 · Dec 31 | 2024-12-31 | −$3.1M | — | — |
| 2024 · Jun 30 | 2024-06-30 | −$16.1M | −$14.7M | — |
| 2023 | 2023-06-30 | −$1.3M | $105,907 | — |
| 2022 | 2022-12-31 | −$1.0M | −$727,690 | — |
| 2022 | 2022-06-30 | −$1.4M | — | — |
| 2021 | 2021-12-31 | −$316,158 | — | — |
Estrella Immunopharma quarterly operating cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$1.8M | −$1.4M | — |
| Q1 2026 | 2026-03-31 | −$6.7M | −$6.2M | — |
| Q4 2025 | 2025-12-31 | −$177,487 | −$3.8M | — |
| Q3 2025 | 2025-09-30 | −$727,332 | $1.5M | — |
| Q2 2025 | 2025-06-30 | −$414,879 | −$123,366 | — |
| Q1 2025 · Mar 31 | 2025-03-31 | −$465,981 | $3.8M | — |
| Q4 2024 | 2024-12-31 | $3.6M | $14.9M | — |
| Q1 2025 · Sep 30 | 2024-09-30 | −$2.2M | −$1.9M | — |
| Q4 2024 | 2024-06-30 | −$291,513 | −$248,268 | — |
| Q3 2024 | 2024-03-31 | −$4.2M | −$4.2M | — |
| Q2 2024 | 2023-12-31 | −$11.3M | −$11.2M | — |
| Q1 2024 | 2023-09-30 | −$275,192 | $825,034 | — |
| Q4 2023 | 2023-06-30 | −$43,245 | $190,198 | — |
| Q1 2023 | 2023-03-31 | −$84,454 | $72,690 | — |
| Q4 2022 | 2022-12-31 | −$108,196 | $185,104 | — |
| Q3 2022 | 2022-09-30 | −$1.1M | −$1.1M | — |
| Q2 2022 | 2022-06-30 | −$233,443 | −$227,388 | — |
| Q1 2022 | 2022-03-31 | −$157,144 | −$156,325 | — |
| Q4 2021 | 2021-12-31 | −$293,300 | — | — |
| Q3 2021 | 2021-09-30 | −$15,984 | — | — |
| Q2 2021 | 2021-06-30 | −$6,055 | — | — |
| Q1 2021 | 2021-03-31 | −$819 | — | — |
Estrella Immunopharma operating cash flow trends
Between the periods ended 2021-12-31 and 2025-12-31, Estrella Immunopharma's operating cash flow decreased from −$316,158 to −$1.8M, a change of −$1.5M. The latest reported quarter, Q2 2026, shows −$1.8M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Estrella Immunopharma source filings ↗